Examples in sarcoma include anaplastic lymphoma kinase (ALK) receptor inhibition with crizotinib in ALK-rearranged inflammatory myofibroblastic tumors and platelet-derived growth factor receptor alpha (PDGFRA) and KIT receptor inhibition in gastrointestinal stromal tumors (GIST) with a panel of agents including imatinib, sunitinib, regorafenib, ripretinib and avapretinib (36–42). This evidence concerns the gene PDGFRA and inflammatory myofibroblastic tumor.